1. Radiolabeling of zoledronic acid with 188Re as a new palliative agent radiotracer in treatment of bone tumors
- Author
-
Mina Tabatabaei, Mohammad Shafiei, Mostafa Erfani, and Alireza Doroudi
- Subjects
0301 basic medicine ,Palliative treatment ,Chemistry ,Health, Toxicology and Mutagenesis ,Public Health, Environmental and Occupational Health ,Bone metastasis ,Pharmacology ,medicine.disease ,Pollution ,Analytical Chemistry ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Zoledronic acid ,Nuclear Energy and Engineering ,030220 oncology & carcinogenesis ,medicine ,Radiology, Nuclear Medicine and imaging ,Spectroscopy ,medicine.drug - Abstract
Zoledronic acid is a bisphosphonates to treat bone problems. Rhenium-188-zoledronic acid could be used as a palliate agent in skeletal metastases. Radiolabeled product was prepared through optimized radiochemical procedures. The organs uptake especially bone uptake assessed in healthy animals mice. The radiochemical purity of the radiotracer was > 95% which was stable up to 24 h. Bone uptake (1.08 ± 0.14% ID/g at 1 h) with retention of activity in bone up to 24 h (0.26 ± 0.06% ID/g) was reached. This radiotracer can be used as a developing candidate for a palliative treatment of bone metastasis.
- Published
- 2018
- Full Text
- View/download PDF